Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior

Current antipsychotics are effective in treating the positive symptoms associated with schizophrenia, but they remain suboptimal in targeting cognitive dysfunction. Recent studies have suggested that positive allosteric modulation of the M1 muscarinic acetylcholine receptor (mAChR) may provide a nov...

Full description

Bibliographic Details
Main Authors: Choy, Kwok H.C., Shackleford, David M., Malone, Daniel T., Mistry, Shailesh N., Patil, Rahul T., Scammells, Peter J., Langmead, Christopher J., Pantelis, Christos, Sexton, Patrick M., Lane, Jonathan R., Christopoulos, Arthur
Format: Article
Published: American Society for Pharmacology and Experimental Therapeutics 2016
Online Access:https://eprints.nottingham.ac.uk/38627/
_version_ 1848795654266028032
author Choy, Kwok H.C.
Shackleford, David M.
Malone, Daniel T.
Mistry, Shailesh N.
Patil, Rahul T.
Scammells, Peter J.
Langmead, Christopher J.
Pantelis, Christos
Sexton, Patrick M.
Lane, Jonathan R.
Christopoulos, Arthur
author_facet Choy, Kwok H.C.
Shackleford, David M.
Malone, Daniel T.
Mistry, Shailesh N.
Patil, Rahul T.
Scammells, Peter J.
Langmead, Christopher J.
Pantelis, Christos
Sexton, Patrick M.
Lane, Jonathan R.
Christopoulos, Arthur
author_sort Choy, Kwok H.C.
building Nottingham Research Data Repository
collection Online Access
description Current antipsychotics are effective in treating the positive symptoms associated with schizophrenia, but they remain suboptimal in targeting cognitive dysfunction. Recent studies have suggested that positive allosteric modulation of the M1 muscarinic acetylcholine receptor (mAChR) may provide a novel means of improving cognition. However, very little is known about the potential of combination therapies in extending coverage across schizophrenic symptom domains. This study investigated the effect of the M1 mAChR positive allosteric modulator BQCA [1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid], alone or in combination with haloperidol (a first-generation antipsychotic), clozapine (a second-generation atypical antipsychotic), or aripiprazole (a third-generation atypical antipsychotic), in reversing deficits in sensorimotor gating and spatial memory induced by the N-methyl-d-aspartate receptor antagonist, MK-801 [(5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine]. Sensorimotor gating and spatial memory induction are two models that represent aspects of schizophrenia modeled in rodents. In prepulse inhibition (an operational measure of sensorimotor gating), BQCA alone had minimal effects but exhibited different levels of efficacy in reversing MK-801–induced prepulse inhibition disruptions when combined with a subeffective dose of each of the three (currently prescribed) antipsychotics. Furthermore, the combined effect of BQCA and clozapine was absent in M1−/− mice. Interestingly, although BQCA alone had no effect in reversing MK-801–induced memory impairments in a Y-maze spatial test, we observed a reversal upon the combination of BQCA with atypical antipsychotics, but not with haloperidol. These findings provide proof of concept that a judicious combination of existing antipsychotics with a selective M1 mAChR positive allosteric modulator can extend antipsychotic efficacy in glutamatergic deficit models of behavior.
first_indexed 2025-11-14T19:35:31Z
format Article
id nottingham-38627
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:35:31Z
publishDate 2016
publisher American Society for Pharmacology and Experimental Therapeutics
recordtype eprints
repository_type Digital Repository
spelling nottingham-386272020-05-04T18:14:01Z https://eprints.nottingham.ac.uk/38627/ Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior Choy, Kwok H.C. Shackleford, David M. Malone, Daniel T. Mistry, Shailesh N. Patil, Rahul T. Scammells, Peter J. Langmead, Christopher J. Pantelis, Christos Sexton, Patrick M. Lane, Jonathan R. Christopoulos, Arthur Current antipsychotics are effective in treating the positive symptoms associated with schizophrenia, but they remain suboptimal in targeting cognitive dysfunction. Recent studies have suggested that positive allosteric modulation of the M1 muscarinic acetylcholine receptor (mAChR) may provide a novel means of improving cognition. However, very little is known about the potential of combination therapies in extending coverage across schizophrenic symptom domains. This study investigated the effect of the M1 mAChR positive allosteric modulator BQCA [1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid], alone or in combination with haloperidol (a first-generation antipsychotic), clozapine (a second-generation atypical antipsychotic), or aripiprazole (a third-generation atypical antipsychotic), in reversing deficits in sensorimotor gating and spatial memory induced by the N-methyl-d-aspartate receptor antagonist, MK-801 [(5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine]. Sensorimotor gating and spatial memory induction are two models that represent aspects of schizophrenia modeled in rodents. In prepulse inhibition (an operational measure of sensorimotor gating), BQCA alone had minimal effects but exhibited different levels of efficacy in reversing MK-801–induced prepulse inhibition disruptions when combined with a subeffective dose of each of the three (currently prescribed) antipsychotics. Furthermore, the combined effect of BQCA and clozapine was absent in M1−/− mice. Interestingly, although BQCA alone had no effect in reversing MK-801–induced memory impairments in a Y-maze spatial test, we observed a reversal upon the combination of BQCA with atypical antipsychotics, but not with haloperidol. These findings provide proof of concept that a judicious combination of existing antipsychotics with a selective M1 mAChR positive allosteric modulator can extend antipsychotic efficacy in glutamatergic deficit models of behavior. American Society for Pharmacology and Experimental Therapeutics 2016-11-01 Article PeerReviewed Choy, Kwok H.C., Shackleford, David M., Malone, Daniel T., Mistry, Shailesh N., Patil, Rahul T., Scammells, Peter J., Langmead, Christopher J., Pantelis, Christos, Sexton, Patrick M., Lane, Jonathan R. and Christopoulos, Arthur (2016) Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior. Journal of Pharmacology and Experimental Therapeutics, 359 (2). pp. 354-365. ISSN 1521-0103 http://jpet.aspetjournals.org/content/359/2/354 doi:10.1124/jpet.116.235788 doi:10.1124/jpet.116.235788
spellingShingle Choy, Kwok H.C.
Shackleford, David M.
Malone, Daniel T.
Mistry, Shailesh N.
Patil, Rahul T.
Scammells, Peter J.
Langmead, Christopher J.
Pantelis, Christos
Sexton, Patrick M.
Lane, Jonathan R.
Christopoulos, Arthur
Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior
title Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior
title_full Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior
title_fullStr Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior
title_full_unstemmed Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior
title_short Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior
title_sort positive allosteric modulation of the muscarinic m1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior
url https://eprints.nottingham.ac.uk/38627/
https://eprints.nottingham.ac.uk/38627/
https://eprints.nottingham.ac.uk/38627/